Mike’s career spans more than two decades in venture capital, following 21 years in senior operating executive roles for leading biotechnology companies. He joined SV Health Investors as a Venture Partner in 2001 and became a Managing Partner in 2002. Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for the Humulin®, Roferon®, and Protropin® programs and was Vice President of Development during the development of Activase®, Nutropin®, and Pulmozyme®. He then started Genentech’s antibody engineering, protein engineering, and small-molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was the Founding Chief Executive Officer (CEO) of Arris Pharmaceutical, MetaXen, ExSAR, and CyThera (now Viacyte).
Mike received his Ph.D. in Chemistry from the California Institute of Technology (Caltech) and went on to do his post-doctoral work at Harvard. He serves on the Board of the Thayer School of Engineering at Dartmouth College. Mike has served on numerous venture and public biotech boards.
